Zenas Biopharma (ZBIO)
Zenas BioPharma, Inc., a clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-based therapies. Its le...
- Open
- 32.050
- High
- 32.973
- Low
- 31.120
- Prev. Close
- 32.440
- Volume
- 461.60K
- Turnover
- 14.56M
- Avg Price
- 31.550
- Bid/Ask Ratio
- 98.02%
- Amplitude
- 5.71%
- 52wk High
- 44.600
- Volume Ratio
- 0.27
- Turnover Ratio
- 1.16%
Zenas Biopharma Analyst Rating
View moreForecast & Rating
Jul 24, 2026Price forecast
$43.5039.02%
Forecast & RatingStrong buy
8analysts
- Strong buy87.50%
- Buy0.00%
- Hold12.50%
- Sell0.00%
- Strong sell0.00%
News
- Market Beat · Jul 29 at 03:29 AM
Zenas BioPharma, Inc. (NASDAQ:ZBIO) Given Average Rating of "Moderate Buy" by Analysts
- StockTitan · Jul 17 at 07:15 AM
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ZBIO Stock News
- PUBT · Jun 17 at 03:15 PM
Zenas BioPharma grants 100,000 stock options, 78,075 RSUs to new hires under 2026 inducement plan
- benzinga_article · Jun 12 at 07:02 AM
Lennar Reports Mixed Q2 Results, Joins Adobe And Other Big Stocks Moving Lower In Friday's Pre-Market Session
- StockTitan · Jun 2 at 10:05 AM
Zenas BioPharma Announces Data from the Registrational Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD), Simultaneously Presented at the EULAR 2026 Congress and Published in the New England Journal of Medicine | ZBIO Stock News
- Simplywall · May 30 at 12:29 PM
Assessing Zenas BioPharma (ZBIO) Valuation After A Strong Year And Recent Share Price Weakness
